 activ esorubicin recurr malign lymphoma southwest oncolog group studi phase II trial esorubicin deoxydoxorubicin southwest oncolog group assess patient non-hodgkin lymphoma nhl hodgkin diseas HD time first relaps esorubicin dose level patient risk excess myelosuppress other interv overal patient treatment complet remiss cr partial remiss pr median durat respons month respons rate histolog subtyp patient favor nhl patient unfavor nhl patient HD twelv patient durabl remiss year leukopenia cell microlit patient sever cell microlit patient clinic sign symptom congest heart failur eject fraction EF patient esorubicin activ agent patient nhl HD time first relaps